Benefits of female “libido” drug flibanserin are marginal, systematic review findsBMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i1217 (Published 01 March 2016) Cite this as: BMJ 2016;352:i1217
- Michael McCarthy
Additional research is needed before the female “libido” drug flibanserin can be recommended for treatment of low sexual desire in women, the authors of a new systematic review and meta-analysis have concluded.1
The benefits of the drug are “marginal,” they said, and treatment was associated with clinically significant adverse events.
“Before flibanserin can be recommended in guidelines and clinical practice, future studies should include women from diverse populations, particularly women with (a history of) somatic and psychological comorbidities, medication use, and surgical menopause,” wrote the lead author, Loes Jaspers, of Erasmus University Medical Center in Rotterdam, Netherlands, and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial